INT173700

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 2003
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 2
Total Number 5
Disease Relevance 0.41
Pain Relevance 1.76

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Edn1) extracellular region (Edn1) cell-cell signaling (Edn1)
cytoplasm (Edn1)
Anatomy Link Frequency
smooth muscle 4
Edn1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 164 99.06 Very High Very High Very High
agonist 88 96.80 Very High Very High Very High
qutenza 56 91.84 High High
Calcitonin gene-related peptide 156 89.36 High High
Potency 12 74.92 Quite High
Inflammation 8 69.56 Quite High
Nerve growth factor 59 69.44 Quite High
Pain 4 67.88 Quite High
Spinal cord 6 52.24 Quite High
Acupuncture 57 50.00 Quite Low
Disease Link Frequency Relevance Heat
Increased Venous Pressure Under Development 13 75.60 Quite High
INFLAMMATION 8 69.56 Quite High
Pain 4 67.88 Quite High
Cancer 4 67.40 Quite High
Cardiovascular Disease 12 66.52 Quite High
Polycystic Ovary Syndrome 64 50.00 Quite Low
Disease 16 38.08 Quite Low
Hypertension 4 14.80 Low Low
Cv Unclassified Under Development 4 5.00 Very Low Very Low Very Low
Follicular Cyst 3 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Binding of Rh-ET-1 (16 nM) to smooth muscle (Fig. 6D) was reduced by BQ788 (1 µM; Fig. 6E) and was prevented by presence of either ET-1 (16 nM) or of both BQ788 (1 µM) and BQ123 (1 µM)[2] indicating selective binding to ETA- and ETB-receptors.
Negative_regulation (prevented) of Rh-ET-1 Binding (Binding) of in smooth muscle
1) Confidence 0.58 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2879375 Disease Relevance 0 Pain Relevance 0.47
Binding of Rh-ET-1 (16 nM) to smooth muscle (Fig. 6D) was reduced by BQ788 (1 µM; Fig. 6E) and was prevented by presence of either ET-1 (16 nM) or of both BQ788 (1 µM) and BQ123 (1 µM)[2] indicating selective binding to ETA- and ETB-receptors.
Negative_regulation (reduced) of Rh-ET-1 Binding (Binding) of in smooth muscle
2) Confidence 0.58 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2879375 Disease Relevance 0 Pain Relevance 0.46
Once established, binding of Rh-ET-1 persisted after washout of free Rh-ET-1 and was not reversed by BQ123 (1 µM; Fig. 6F) indicating quasi-irreversible receptor-binding of the agonist.
Neg (not) Negative_regulation (reversed) of Rh-ET-1 Binding (binding) of associated with agonist
3) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2879375 Disease Relevance 0.06 Pain Relevance 0.45
Several classes of low molecular weight ETA-selective or mixed ET-receptor antagonists have been developed primarily on the basis of prevention of the binding of ET-1 to its receptors[4], [5], [6], [19], [20], [21].
Negative_regulation (prevention) of ET-1 Binding (binding) of associated with antagonist
4) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2879375 Disease Relevance 0.35 Pain Relevance 0.22
The amount of ET-1 required to reduce the binding of the radioligand by 50% (IC50) was 7.4 pmol/l.
Negative_regulation (reduce) of ET-1 Binding (binding) of
5) Confidence 0.37 Published 2003 Journal Reprod Biol Endocrinol Section Body Doc Link PMC155675 Disease Relevance 0 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox